Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype

American Journal of Transplantation

Volumn 16, Issue 9, 2016, Pages 2670-2675

  Pallet, N ^a,b,c   Etienne, I ^d   Buchler, M ^e   Bailly, E ^e   Hurault de Ligny, B ^f   Choukroun, G ^g   Colosio, C ^h   Thierry, A ⁱ   Vigneau, C ^j   Moulin, B ^k   Le Meur, Y ^l   Heng, A E ^m   Legendre, C ⁿ   Beaune, P ^a,b,c   Loriot, M A ^a,b,c   Thervet, E ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l BREST UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

calcineurin inhibitor: tacrolimus; clinical research practice; genetics; immunosuppressant; immunosuppression immune modulation; kidney transplantation nephrology; patient survival; pharmacokinetics pharmacodynamics; translational research science

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FEMALE; GENOTYPE; GRAFT SURVIVAL; HUMAN; INCIDENCE; INFECTION; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT;

EID: 84984597146     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13788     Document Type: Article

References (22)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562–2575.
2. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002; 359: 741–746.
3. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit 2009; 31: 139–152.
4. Elens L, Hesselink DA, van Schaik RH, van Gelder T. Pharmacogenetics in kidney transplantation: Recent updates and potential clinical applications. Mol Diagn Ther 2012; 16: 331–345.
5. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233–1235.
6. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574–1583.
7. Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharmacogenomics J 2015; 15: 38–48.
8. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
9. Elens L, Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RH. Clinical implementation of pharmacogenetics in kidney transplantation: Calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol 2014; 77: 715–728.
10. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914–919.
11. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3: S1–S155.
12. Shuker N, Bouamar R, van Schaik RHN, et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant 2016. doi: 10.1111/ajt.13691.
13. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and meta-analysis. Pharmacogenet Genomics 2012; 22: 642–645.
14. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721–726.
15. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials(†). Am J Transplant 2013; 13: 1253–1261.
16. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P. The challenge of achieving target drug concentrations in clinical trials: Experience from the Symphony study. Transplantation 2009; 87: 1360–1366.
17. Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: A review. Ann Transplant 2012; 17: 111–121.
18. Storset E, Asberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients—A prospective, randomized study. Transplantation 2015; 99: 2158–2166.
19. Bloch J, Hazzan M, Van der Hauwaert C, et al. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. Pharmacogenomics 2014; 15: 2011–2024.
20. Moore J, McKnight AJ, Dohler B, et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol 2012; 23: 1891–1899.
21. Lunenburg CA, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer 2015; 54: 40–48.
22. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992–3995.